Share Prices & Company Research

Stockbroking

Dechra Pharmaceuticals

Current Price 2562.00p Bid 2558.00p Ask 2562.00p Change -0.31%
Last Updated: 18/02/2019 12:23. Prices delayed by at least 15 minutes.
Call 0113 243 6941 or search for your local office

Company Overview

Dechra Pharmaceuticals plc is an international specialist veterinary pharmaceuticals and relates products business. Our expertise is in the development, manufacture and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.

Financial Highlights Year Ended 30/06/2018

Turnover
£407.10m
Operating Profit
£34.10m
Dividend Yield
0.99
Dividend Per Share
25.50
Dividend Cover
1.46
P/E Ratio
68.96

Key Personnel

Ian David Page
Chief Executive
Richard John Cotton
Chief Financial Officer
Anthony Gerard Griffin
Executive Director
William Anthony Rice
Non-Executive Chairman
Julian Spenser Heslop
Non-Executive Director
Ishbel Jean Stewart Macpherson
Non-Executive Director
Dr Lawson Macartney
Non-Executive Director
Lisa Bright
Non-Executive Director

Stock Details

EPIC
DPH
ISIN
GB0009633180
Shares in Issue
102,567,632
Market cap
£2,633.94m

Analyst Views (2)

Strong Buy
 
50.00%
Buy
 
0.00%
Hold
 
50.00%
Sell
 
0.00%
Strong Sell
 
0.00%
The above information represents a selection of the views published in the last 120 days by analysts. It is subject to change without notice and doesn't reflect view held by Redmayne Bentley and is not advice.

Price Summary

Mid Price
2560.00p
Bid Price
2558.00p
Ask Price
2562.00p
Volume
37473
Change Today
-8.00p
% Change Today
-0.31%
Open
2578.00p
Previous Close
2568.00p
Intraday High
2612.00p
Intraday Low
2540.00p
52 Week High
3180.00p
52 Week Low
1992.00p
52 week high and low figures quoted above are calculated from intraday price data.

Intra-Day Chart

Dechra Pharmaceuticals Intra-day Chart

Dechra Pharmaceuticals News

News in this section is provided by AJ Bell

Broker Forecast - HSBC issues a broker note on Dechra Pharmaceuticals PLC 12 Feb 2019 | 13:00 Chinese slowdown fears weigh on global equities 14 Jan 2019 | 16:46 FTSE losses accelerate as China fears persist 14 Jan 2019 | 12:08 Dechra Pharmaceuticals first-half performance meets expectations 14 Jan 2019 | 07:35 Director Deals - Dechra Pharmaceuticals PLC (DPH) 19 Dec 2018 | 09:00 Dechra Pharmaceuticals completes acquisition of Venco 18 Dec 2018 | 07:24 Broker Forecast - RBC Capital Markets issues a broker note on Dechra Pharmaceuticals PLC 23 Nov 2018 | 11:00 Director Deals - Dechra Pharmaceuticals PLC (DPH) 24 Oct 2018 | 15:35 Director Deals - Dechra Pharmaceuticals PLC (DPH) 24 Oct 2018 | 15:35 Director Deals - Dechra Pharmaceuticals PLC (DPH) 24 Oct 2018 | 15:35 Director Deals - Dechra Pharmaceuticals PLC (DPH) 24 Oct 2018 | 15:35 Director Deals - Dechra Pharmaceuticals PLC (DPH) 23 Oct 2018 | 12:20 UK stocks open 0.3% higher after China market gains 19 Oct 2018 | 08:47 Dechra Q1 performance in line; acquires Venco for £37.8m 19 Oct 2018 | 07:40 Dechra Pharmaceuticals acquires Caledonian for £4.4m 08 Oct 2018 | 07:17 FTSE gains positive momentum on sliding pound 03 Sep 2018 | 16:44 Brexit woes boost FTSE 03 Sep 2018 | 11:49 Broker Forecast - Numis issues a broker note on Dechra Pharmaceuticals PLC 03 Sep 2018 | 10:10 FTSE opens 0.5% higher as Brexit woes hit Sterling 03 Sep 2018 | 09:04 Dechra Pharmaceuticals reports modest profit growth 03 Sep 2018 | 08:07 Broker Forecast - Numis issues a broker note on Dechra Pharmaceuticals PLC 10 Jul 2018 | 11:10 Dechra Pharmaceuticals expects annual performance to meet expectations 10 Jul 2018 | 07:47 Director Deals - Dechra Pharmaceuticals PLC (DPH) 05 Mar 2018 | 12:30 Director Deals - Dechra Pharmaceuticals PLC (DPH) 26 Feb 2018 | 17:30 Major stock markets enjoy positive start to the week 26 Feb 2018 | 16:53 FTSE follows Asia with bright start to the week 26 Feb 2018 | 11:57 Dechra Pharmaceuticals revenue grows 11.2% amid strong performance in North America 26 Feb 2018 | 10:08

Assets (£m)

Data has been provided by AJ Bell

Reporting Date
30 Jun 2018
30 Jun 2017
Tangible Assets
45.3
45.2
Intangible Assets & Goodwill
709.8
396.3
Investments & Other Non-Current Assets
14.3
11.6
Total Non-Current Assets
769.4
453.1
Inventory
86.6
56.5
Trade & Receivables
81.6
67.3
Cash & Receivables
79.7
61.2
Other Current Assets & Assets Held for Resale
0.0
0.0
Total Assets
1,017.3
638.1

Liabilities (£m)

Data has been provided by AJ Bell

Reporting Date
30 Jun 2018
30 Jun 2017
Short Term Liabilities
91.6
66.4
Long Term Liabilities
420.7
269.0
Other Liabilities / Pension etc
0.0
0.0
Total Liabilities
512.3
335.4

Net Assets (£m)

Data has been provided by AJ Bell

Reporting Date
30 Jun 2018
30 Jun 2017
Net Assets
505.0
302.6

Equity (£m)

Data has been provided by AJ Bell

Reporting Date
30 Jun 2018
30 Jun 2017
Share Capital
1.0
0.9
Minority Interests
0.0
1.6
Retained Earnings
125.5
107.4
Share Premium Account
359.3
173.4
Other Equity
19.2
19.3
Total Equity
505.0
302.6

Cashflow (£m)

Data has been provided by AJ Bell

Reporting Date
30 Jun 2018
30 Jun 2017
Cashflow from Operating Activities
64.0
77.4
Cashflow Before Financing
-177.7
20.2
Increase / Decrease in Cash
16.1
21.7

Income (£m)

Data has been provided by AJ Bell

Reporting Date
30 Jun 2018
30 Jun 2017
Turnover
407.1
359.3
Cost of Sales
184.7
167.6
Gross Profit
222.4
191.7
Operating Profit
34.1
33.2
Pre-Tax Profit
28.9
28.6
Profit / Loss for the Year
36.1
26.1

Dividend History

Data has been provided by AJ Bell

Period
Ex-Dividend Date
Payment Date
H2 Dividend
25 Oct 2018
16 Nov 2018
H1 Dividend
08 Mar 2018
06 Apr 2018
H2 Dividend
26 Oct 2017
17 Nov 2017
H1 Dividend
09 Mar 2017
07 Apr 2017
H2 Dividend
27 Oct 2016
18 Nov 2016
H1 Dividend
10 Mar 2016
06 Apr 2016
H2 Dividend
29 Oct 2015
20 Nov 2015
H1 Dividend
12 Mar 2015
07 Apr 2015
H2 Dividend
06 Nov 2014
21 Nov 2014
H1 Dividend
12 Mar 2014
08 Apr 2014
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.